Please ensure Javascript is enabled for purposes of website accessibility

Is Pfizer Stock a Buy After an FDA Panel Recommended Boosters for Ages 65 and Up?

By Keith Speights – Sep 21, 2021 at 5:52AM

Key Points

  • An FDA advisory committee voted to recommend Americans over 65 receive Pfizer COVID vaccine boosters.
  • While it isn't all that Pfizer wanted, the recommendation could mean millions of more doses will be given.
  • The recommendation isn't a compelling reason to buy Pfizer, but there are other reasons to like the stock.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Yes -- and no.

A partial victory is better than a complete loss. Pfizer (PFE 0.84%) and BioNTech (BNTX 0.60%) are experiencing this firsthand.

The two partners had hoped that a U.S. Food and Drug Administration (FDA) advisory committee would recommend COVID-19 vaccine boosters for all Americans ages 16 and up. However, on Friday the panel voted 16-2 against recommending Pfizer-BioNTech boosters for the wide age range.

It wasn't all bad news for Pfizer and BioNTech, though. The FDA advisory committee also voted unanimously to recommend boosters for Americans ages 65 and up as well as for individuals of any age at high risk of severe COVID-19. Could Pfizer stock actually be a smart pick to buy after the partial victory?

A masked, gloved, and shielded healthcare professional holding a syringe with needle and vaccine vial near the arm of a masked patient.

Image source: Getty Images.

A silver lining

The FDA still must make a decision on boosters for the Pfizer-BioNTech vaccine. If the agency follows the recommendation of the panel and the Centers for Disease Control and Prevention (CDC) agree, a lot of booster shots could be on the way soon.

There are around 52.4 million Americans ages 65 and older in 2018, according to the U.S. Department of Health and Human Services' Administration on Aging. That number is undoubtedly higher today. 

Vaccination rates are highest among older Americans than for any other age group. Nearly 85% of people between 65 and 74 have been fully vaccinated, according to the CDC. Almost 80% of Americans ages 75 and older have been fully vaccinated.

We don't know how many of these individuals received Pfizer's and BioNTech's Comirnaty COVID-19 vaccine. However, on an overall basis, Comirnaty makes up close to 57% of all COVID-19 vaccine doses given so far.

Back-of-the-envelope calculations indicate that in the ballpark of 25 million Comirnaty boosters could be administered over the coming months if the FDA and CDC give a green light to the boosters. Based on previous pricing for the vaccine, the total cost of boosters for the groups recommended by the FDA panel could approach $500 million. 

The gravy train has already left the station

At first glance, the potential for an extra $500 million or so over the next few months could seem like a big deal. However, there are several reasons why it's nothing to get all that excited about.

Most importantly, there probably won't be any "extra" money coming to either company over the near term due to boosters. The U.S. has already ordered a total of 500 million doses from Pfizer and BioNTech plus another 500 million doses to donate to other countries. At least for now, it's unlikely that additional doses will be bought by the government for vaccinating Americans.

Remember, too, that Pfizer and BioNTech split the profits from Comirnaty. Even if the companies could count on additional U.S. government orders for boosters, the financial impact for Pfizer wouldn't make a huge impact. The company generated $19 billion in revenue in the second quarter and nearly $5.6 billion in profits. 

Buy Pfizer?

There's really no compelling reason to buy Pfizer stock based on the FDA advisory committee recommendation. However, there are other reasons why investors might want to seriously consider the big pharma stock

The need for annual boosters for everyone is still a real possibility. If Pfizer can count on strong recurring revenue from Comirnaty for years to come, the stock will look a lot more attractive.

Of course, Pfizer doesn't depend solely on its COVID-19 vaccine. The company has other growth drivers that investors should like, notably including rare heart disease drug Vyndaqel/Vyndamax and blood thinner Eliquis.

Pfizer's pipeline could deliver more big winners. A COVID-19 pill could be on the way. The drugmaker also has more than 20 other late-stage programs. It's also adding to the pipeline through deals, including plans to acquire Trillium Therapeutics.

Last, but not least, there's Pfizer's dividend. Many income investors will like the dividend yield that currently tops 3.5%. 

Pfizer stock looks like a pretty good pick for some investors. But any approval for boosters for older Americans doesn't make a big difference in the decision to buy the stock one way or another.

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$50.55 (0.84%) $0.42
BioNTech Se Stock Quote
BioNTech Se
BNTX
$168.03 (0.60%) $1.00
Trillium Therapeutics Stock Quote
Trillium Therapeutics
TRIL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
371%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.